Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASM8
- Development stage
- Phase 2
- Lead developer
- Syntara
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Inhalation
01
Overview
ASM8 is an inhaled antisense oligonucleotide therapy developed for the treatment of moderate-to-severe asthma and allergic asthma. It consists of two modified antisense oligonucleotides that target the beta subunit (βc) shared by the interleukin-3 (IL-3), interleukin-5 (IL-5), and granulocyte-macrophage colony-stimulating factor (GM-CSF) receptors, as well as the chemokine receptor CCR3. By antagonizing these targets, ASM8 aims to reduce airway inflammation by inhibiting eosinophil recruitment and activity in asthmatic patients. Clinical studies demonstrated that inhaled ASM8 reduced sputum eosinophils and attenuated both early and late airway responses following allergen challenge in mild allergic asthmatics[1][4]. Despite promising results in phase 2 trials, development has been discontinued.
- Other names
- ASM 8ASM8ASM-8TPI-ASM8TPI-ASM-8TPI-ASM 8
02
Targets
CCR3 (C-C chemokine receptor type 3)CSF2RB (Cytokine receptor common subunit beta)
Beyond the preview
Go deeper on ASM8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASM8.